{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:50:26Z","timestamp":1790470226670,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.humpath.2019.04.020","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T23:31:35Z","timestamp":1557358295000},"page":"80-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA"],"prefix":"10.1016","volume":"90","author":[{"given":"Rina","family":"Kansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2019.04.020_bb0005","first-page":"626","article-title":"Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.humpath.2019.04.020_bb0010","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.04.020_bb0015","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting\u2014Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2019.04.020_bb0020","series-title":"Pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"Jaffe","year":"2001"},{"key":"10.1016\/j.humpath.2019.04.020_bb0025","doi-asserted-by":"crossref","unstructured":"Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100\u20132292-302.","DOI":"10.1182\/blood-2002-04-1199"},{"key":"10.1016\/j.humpath.2019.04.020_bb0030","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.humpath.2019.04.020_bb0035","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Classification (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.04.020_bb0040","article-title":"Boston","author":"Swerdlow","year":"2015","journal-title":"MA"},{"key":"10.1016\/j.humpath.2019.04.020_bb0045","doi-asserted-by":"crossref","unstructured":"Kansal R. Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification. Cancer Biol Med 2016;13:41\u201354. https:\/\/doi.org\/10.28092\/j.issn.2095-3941.2016.0001.","DOI":"10.20892\/j.issn.2095-3941.2016.0001"},{"key":"10.1016\/j.humpath.2019.04.020_bb0050","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.04.020_bb0055","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.humpath.2019.04.020_bb0060","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.04.020_bb0065","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2019.04.020_bb0070","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2019.04.020_bb0075","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/85820","article-title":"Dominant-negative mutations of CEBPA, encoding CCAAT\/enhancer binding protein-alpha (C\/EBP alpha) in acute myeloid leukemia","volume":"27","author":"Pabst","year":"2001","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.humpath.2019.04.020_bb0080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.gpb.2015.11.004","article-title":"EDISON-WMW: exact dynamic programing solution of the Wilcoxon-Mann-Whitney test","volume":"14","author":"Marx","year":"2016","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"10.1016\/j.humpath.2019.04.020_bb0085","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1182\/blood-2005-05-2168","article-title":"Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance","volume":"106","author":"Verhaak","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.04.020_bb0090","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1182\/blood-2005-05-2164","article-title":"Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations","volume":"106","author":"D\u00f6hner","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.04.020_bb0095","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2005-04-1733","article-title":"Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia","volume":"106","author":"Suzuki","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.04.020_bb0100","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","article-title":"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)","volume":"107","author":"Thiede","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.04.020_bb0105","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2005-05-2174","article-title":"Prevalence, clinical profile and prognosis of NPM mutations in AML with normal karyotype","volume":"106","author":"Boissel","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.04.020_bb0110","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.04.020_bb0115","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/JCO.2009.25.1496","article-title":"Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study","volume":"28","author":"Becker","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2019.04.020_bb0120","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.bjc.6604977","article-title":"Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis","volume":"100","author":"Pabst","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2019.04.020_bb0125","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1200\/JCO.2004.06.060","article-title":"CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations","volume":"22","author":"Frohling","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2019.04.020_bb0130","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.2008.21.6010","article-title":"Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome","volume":"28","author":"Dufour","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2019.04.020_bb0135","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO.2009.26.2501","article-title":"Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations","volume":"28","author":"Green","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2019.04.020_bb0140","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2008-09-179895","article-title":"Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome","volume":"113","author":"Wouters","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.04.020_bb0145","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood-2010-09-307280","article-title":"Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity","volume":"117","author":"Taskesen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2019.04.020_bb0150","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/leu.2013.273","article-title":"The role of different genetic subtypes of CEBPA mutated AML","volume":"28","author":"Fasan","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2019.04.020_bb0155","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3324\/haematol.2016.151910","article-title":"CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features","volume":"102","author":"Mannelli","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2019.04.020_bb0160","unstructured":"Kansal R. Familial acute myeloid leukemia. In: Liu D, editor. Handbook of tumor syndromes, Taylor & Francis CRC Press, [in press]."},{"key":"10.1016\/j.humpath.2019.04.020_bb0165","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa041331","article-title":"Mutation of CEBPA in familial acute myeloid leukemia","volume":"351","author":"Smith","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2019.04.020_bb0170","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2015-05-647172","article-title":"Disease evolution and outcomes in familial AML with germline CEBPA mutations","volume":"126","author":"Tawana","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.humpath.2019.04.020_bb0175","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1002\/ajh.23744","article-title":"The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies","volume":"89","author":"Fircanis","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2019.04.020_bb0180","unstructured":"Madanat YF, Radivoyevitch T, Nazha A, et al. Mutational signatures associated with intensity and duration of smoking in myelodysplastic syndromes. Blood 2017;130:424 (abstract)."},{"key":"10.1016\/j.humpath.2019.04.020_bb0185","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817719300851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817719300851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:36:13Z","timestamp":1758645373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817719300851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":37,"alternative-id":["S0046817719300851"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2019.04.020","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2019.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}